Next-generation antibody (NGA) therapeutics with antibody architecture modifications
represent a key area of monoclonal antibody (mAb) research and development (R&D) …

The annual European Antibody Congress (EAC) has traditionally been the key event for
updates on critical scientific advances in the antibody field, and 2013 was no exception …

HER2-targeted immunotherapy consists of monoclonal antibodies (eg trastuzumab,
pertuzumab), bispecific antibodies (eg MM-111, ertumaxomab) and activated T cells armed …

The ErbB family is well known for its significance in oncogenesis. As bad prognostic
markers, overexpressed or mutated ErbB1 and ErbB2 have an important role in the …

Targeted therapeutics such as monoclonal antibodies (mAbs) have proven successful as
cancer drugs. To profile products that could be marketed in the future, we examined the …

Advances in our understanding of cancer biology have enabled drug development to
progress towards better targeted therapies that are both more effective and safer owing to …

Drug discovery may not be rocket science, but the guided missile concept has nevertheless
taken hold. With the US Food and Drug Administration (FDA)'s recent approval of …

Objective: To review the pharmacology, pharmacokinetics, efficacy, adverse effects, drug-
drug interactions, dosage and administration, and formulary considerations for ado …

Antibody‑drug conjugates (ADCs) are anticancer drugs that combine cytotoxic small‑
molecule drugs (payloads) with monoclonal antibodies through a chemical linker and that …

Antibody‐drug conjugates (ADCs) have emerged as a promising class of biologics since the
first approval of Gemtuzumab ozogamicin in 2000. Compared to small molecule drugs …